ProCE Banner Activity

Interactive Decision Support Tool: MCL Expert Treatment Guidance

Tool

Get recommendations from 5 experts on MCL for your specific patient case using this Interactive Decision Support Tool.

Released: April 21, 2023

Share

Faculty

Stephen Ansell

Stephen Ansell, MD, PhD

Professor of Medicine
Department of Hematology
Mayo Clinical Cancer Center
Rochester, Minnesota

Ian Flinn

Ian Flinn, MD, PhD

Chief Scientific Officer
OneOncology
Nashville, Tennessee

Christopher R. Flowers

Christopher R. Flowers, MD, MS

Department Chair
Department of Lymphoma/Myeloma, Division of Cancer Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas

John P. Leonard

John P. Leonard, MD

Senior Associate Dean for Innovation and initiatives
Chair (Interim), Weill Department of Medicine
Richard T. Silver Distinguished Professor of Hematology and Medical Oncology
Weill Cornell Medicine/NewYork-Presbyterian
New York, New York

Julie M. Vose

Julie M. Vose, MD, MBA

Payne Presidential Chair
Chief, Division of Hematology/Oncology
University of Nebraska Medical Center
Buffett Cancer Center
Omaha, Nebraska

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Lilly.

Lilly

Faculty Disclosure

Primary Author

Stephen Ansell, MD, PhD

Professor of Medicine
Department of Hematology
Mayo Clinical Cancer Center
Rochester, Minnesota

Stephen Ansell, MD, PhD: researcher: ADC Therapeutics, Affimed, AstraZeneca, Bristol-Myers Squibb, Pfizer, SeaGen, Takeda.

Ian Flinn, MD, PhD

Chief Scientific Officer
OneOncology
Nashville, Tennessee

Ian W. Flinn, MD, PhD: consultant (paid to institution): AbbVie, AstraZeneca, BeiGene, Century Therapeutics, Genentech, Genmab, Hutchison MediPharma, Iksuda, InnoCare Pharma, Janssen, Kite, MorphoSys, Myeloid Therapeutics, Novartis, Nurix, Pharmacyclics, Roche, Secura Bio, Servier, Takeda, TG Therapeutics, Verastem, Vincerx, Xencor; researcher (paid to institution): 2seventy bio, AbbVie, Acerta, Agios, ArQule, AstraZeneca, BeiGene, Biopath, Bristol-Myers Squibb, CALIBR, CALGB, Celgene, City of Hope National Medical Center, Constellation, Curis, CTI Biopharma, Epizyme, Fate Therapeutics, Forma, Forty Seven, Genentech, Gilead Sciences, InnoCare, IGM Biosciences, Incyte, Infinity, Janssen, Kite Pharma, Loxo, Merck, Millennium, MorphoSys, Myeloid Therapeutics, Novartis, Nurix, Pfizer, Pharmacyclics, Portola, Rhizen, Roche, Seattle Genetics, Tessa Therapeutics, TCR2 Therapeutics, TG Therapeutics, Trillium, Triphase Research & Development Corp, Unum Therapeutics, Verastem.

Christopher R. Flowers, MD, MS

Department Chair
Department of Lymphoma/Myeloma, Division of Cancer Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas

Christopher R. Flowers, MD, MS: consultant/advisor/speaker: AstraZeneca, Bayer, BeiGene, BioAscend, Bristol Myers Squibb, Celgene, Curio Sciences, Denovo Biopharma, Epizyme/Incyte, Foresight Diagnostics, Genentech/Roche, Genmab, MEI Pharmaceuticals, MorphoSys AG, N-Power, Pharmacyclics/Janssen, SeaGen; stock options: Foresight Diagnostics, N-Power; researcher (paid to institution): 4D, AbbVie, Acerta, Adaptimmune, Allogene, Amgen, Bayer, Celgene, Cellectis, EMD, Gilead, Genentech/Roche, Guardant, Iovance, Janssen, Kite, MorphoSys, Nektar, Novartis, Pfizer, Pharmacyclics, Sanofi, Takeda, TG Therapeutics, Xencor, Ziopharm.

John P. Leonard, MD

Senior Associate Dean for Innovation and initiatives
Chair (Interim), Weill Department of Medicine
Richard T. Silver Distinguished Professor of Hematology and Medical Oncology
Weill Cornell Medicine/NewYork-Presbyterian
New York, New York

John P. Leonard, MD: consulting/advisor/speaker: AbbVie, Astellas, AstraZeneca, Bayer, BeiGene, Bristol-Myers Squibb, Calithera, Caribou Biosciences, Constellation, Eisai, Epizyme, Genmab, Grail, Incyte, Janssen, Karyopharm, Lilly, Merck, Mustang Bio, Pfizer, Roche/Genentech, Second Genome, Sutro.

Julie M. Vose, MD, MBA

Payne Presidential Chair
Chief, Division of Hematology/Oncology
University of Nebraska Medical Center
Buffett Cancer Center
Omaha, Nebraska

Julie M. Vose, MD, MBA: consultant/advisor/speaker: AbbVie, MEI Pharma; researcher: Epizyme, Kite, Loxo, Novartis.